Lead Product(s) : Neuroplastogen
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Discovery
Sponsor : U.S. Department of Defense
Deal Size : $0.8 million
Deal Type : Funding
Delix Awarded Grant from US Department of Defense for Neuroplastogen to Treat Hearing Loss
Details : The financing will support the advancement of a neuroplastogen, a novel, first-in-class, non-toxic, that has been found to repair cochlear synaptopathy that contribute to hidden hearing loss.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 04, 2024
Lead Product(s) : Neuroplastogen
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Discovery
Sponsor : U.S. Department of Defense
Deal Size : $0.8 million
Deal Type : Funding
Lead Product(s) : AAV-Based Genetic Medicine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the collaboration, Astellas Gene Therapies, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus based genetic medicine and translational capabilities to complete experiments in pre-clinical...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 05, 2022
Lead Product(s) : AAV-Based Genetic Medicine
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Collaboration and licensing agreement with Boehringer Ingelheim will advance the discovery, development, and commercialization of novel therapies for sensorineural hearing loss (SHNL), where there are currently no approved pharmacological therapies.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 13, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?